In Arthritis Patients Taking NSAIDs, NT-ProBNP Is A Predictor Of CV Risk
The role of N-terminal pro-B-type natriuretic peptide (NT-proBNP, a protein thought to be a regulator of cardiovascular function) as a robust, non-invasive predictor of cardiovascular (CV) risk in patients with arthritis taking cyclooxygenase inhibitors has been reinforced by the results of a multinational study presented at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.
Read the full story here
-
Researchers Study Use Of Preoperative Beta-blockers
Angiotech Pharmaceuticals And Partner Athersys Announce Updated Results From Phase I Study Of Multistem(R) In Heart Attack Patients
Drug-coated stents could boost death rate in heart attack patients
Celera Announces Issuance Of United States Patent Relating To LPA Gene Variant Associated With Increased Risk For Myocardial Infarction
Self-Discharged Cardiovascular Patients Rack up Higher Hospital Costs
